Sinotherapeutics (SH:688247)2026-02-27 07:50Financial Performance - Total revenue for 2025 was CNY 446.50 million, a decrease of 12.73% compared to the previous year[3] - Net profit attributable to shareholders was CNY 48.95 million, down 61.67% year-on-year[5] - Net profit excluding non-recurring gains and losses decreased by 72.47% to CNY 31.38 million[5] - Basic earnings per share fell by 60.65% to CNY 0.11[3] - The weighted average return on net assets decreased by 6.56 percentage points to 3.81%[3] Assets and Equity - Total assets at the end of the reporting period were CNY 1,437.68 million, a decline of 1.07%[5] - Shareholders' equity attributable to the parent company increased by 1.61% to CNY 1,293.45 million[5] Factors Affecting Performance - The decline in revenue and profit was primarily due to price reductions from national drug procurement policies and increased competition in overseas markets[6] - The company recognized impairment losses on receivables, inventory, and goodwill, negatively impacting net profit[6] Audit and Investment Risks - The financial data presented is preliminary and subject to final audit, highlighting potential investment risks[9]